Corning Announces Collaboration with TAP Biosystems for Cell Culture Automation

Image Alt Text

Corning Announces Collaboration with TAP Biosystems for Cell Culture Automation

Corning Announces Collaboration with TAP Biosystem

News Releases
Life Sciences
Corning Announces Collaboration with TAP Biosystems for Cell Culture Automation
Corning Announces Collaboration with TAP Biosystems for Cell Culture Automation
CORNING, N.Y. | Corning Incorporated | 2012年6月4日
Automation support for the HYPERStack®-120 Vessel will enable better control, more consistent results for bioprocess customers 

Corning Life Sciences, a segment of Corning Incorporated (NYSE: GLW), today announced it has entered into a collaboration with TAP Biosystems to provide a manufacturing automation solution for large-scale, attachment-dependent cell culture. Under terms of the agreement, TAP will develop an automated system capable of manipulating up to four Corning® HYPERStack ®-120 Cell Culture Vessels simultaneously, providing better control and more consistent results to large bioprocess customers who require high-throughput manufacturing. 

“Biotherapeutic manufacturers are faced with developing more product of better, first-time quality at less total manufactured cost,” said Ken Ludwig, business manager, bioprocess and cell therapy, Corning Life Sciences. “To meet and exceed the needs of these customers, we seek ways to deliver innovative technologies to the market that improve results, increase efficiencies, and lower costs. Our collaboration with TAP is another proof point of that commitment and to our focus on both automation and bioprocess.”

“TAP is excited to be working on another custom project with Corning Life Sciences,” said Dave Thomas, product manager, Integrated Cell Culture Systems, TAP Biosystems. “There is a strong need for automated tools to improve production efficiency and we believe that the combination of Corning and TAP expertise will provide a significant step forward in this area.”

This latest project follows a number of successful collaborations between the two companies.  These include implementing Corning cryogenic vials on TAP’s Fill It automated dispensing system and HYPERFlask ® cell culture vessels on TAP’s CompacT SelecT™ automated cell culture system.

The HYPERStack cell culture vessel features a unique, multi-layered design based on Corning’s gas-permeable film technology and delivers more cells in the same volumetric footprint compared to current stacked-plate products. The increased surface area enables researchers to produce more cells from the same cell population and reduce variability, and use fewer vessels, which saves space and labor.

Corning’s cell culture vessels for bioprocessing support suspension and attachment culture in various capacities and provide solutions from cell line development, to seed train, to manufacturing.

Corning Life Sciences brings new and innovative laboratory technologies to researchers worldwide and helps customers succeed by providing innovative, high-quality products and services in the areas of polymer science, biochemistry and molecular biology, glass melting and forming, surface modification, and characterization science.

To learn more about Corning’s automation solution for the HYPERStack-120 Cell Culture Vessel or any Corning Life Sciences products, please contact a customer service representative at 1-800-492-1110, toll free in the United States; (+1) 1-978-442-2200 internationally; or visit .

Forward-Looking and Cautionary Statements
This press release contains “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995), which are based on current expectations and assumptions about Corning’s financial results and business operations, that involve substantial risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: the effect of global political, economic and business conditions; conditions in the financial and credit markets; currency fluctuations; tax rates; product demand and industry capacity; competition; reliance on a concentrated customer base; manufacturing efficiencies; cost reductions; availability of critical components and materials; new product commercialization; pricing fluctuations and changes in the mix of sales between premium and non-premium products; new plant start-up or restructuring costs; possible disruption in commercial activities due to terrorist activity, armed conflict, political or financial instability, natural disasters, adverse weather conditions, or major health concerns; adequacy of insurance; equity company activities; acquisition and divestiture activities; the level of excess or obsolete inventory; the rate of technology change; the ability to enforce patents; product and components performance issues; retention of key personnel; stock price fluctuations; and adverse litigation or regulatory developments. These and other risk factors are detailed in Corning’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.

About Corning Incorporated
Corning Incorporated ( ) is the world leader in specialty glass and ceramics. Drawing on more than 160 years of materials science and process engineering knowledge, Corning creates and makes keystone components that enable high-technology systems for consumer electronics, mobile emissions control, telecommunications and life sciences. Our products include glass substrates for LCD televisions, computer monitors and laptops; ceramic substrates and filters for mobile emission control systems; optical fiber, cable, hardware & equipment for telecommunications networks; optical biosensors for drug discovery; and other advanced optics and specialty glass solutions for a number of industries including semiconductor, aerospace, defense, astronomy, and metrology.

About TAP Biosystems
TAP Biosystems provides innovative automation systems and consumables to improve productivity in life science research, development and production. For over 20 years, TAP has been the leader in the design and development of automated cell culture systems with applications in bioprocessing, drug discovery and regenerative medicine. TAP also develops automation solutions in the emerging fields of biologics and cell-based therapies, including stem cell research and tissue engineering. For More information please visit .